Literature DB >> 16956044

[Lysophosphatidic acid in ovarian cancer patients].

I Sedlákova1, J Vávrová, J Tosner, L Hanousek.   

Abstract

OBJECTIVE: To compare plasma lysophosphatidic acid (LPA) level in ovarian cancer patients and women without ovarian pathology.
DESIGN: Prospective study.
SETTING: Department of Gynecology and Obstetrics, University Hospital, Hradec Králové.
METHODS: The method for LPA level analyze with its specification by capillary electrophoresis using indirect ultraviolet detection has been implementated. Since the beginning of this project venous blood samples from 103 patients (60 patients with ovarian cancer, 43 patients without ovarian pathology) have been obtained.
RESULTS: Plasma LPA levels were elevated in ovarian cancer patients (sigma LPA Med 19.9 micromol/l, Range 4.5-42.7 micromol/l). Patients without ovarian pathology (n=35) (sigma LPA Med 2.6 micromol/l, Range 0.9-22.9 micromol/l, P<0,001) had statistically significant lower plasma LPA level compared with ovarian cancer patients.
CONCLUSION: Lysophosphatidic acid appears useful as diagnostic marker of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16956044

Source DB:  PubMed          Journal:  Ceska Gynekol        ISSN: 1210-7832


  9 in total

1.  Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.

Authors:  Iva Sedláková; Jaroslava Vávrová; Jindřich Tošner; Ladislav Hanousek
Journal:  Tumour Biol       Date:  2011-04

2.  Spiroguanidine rhodamines as fluorogenic probes for lysophosphatidic acid.

Authors:  Lei Wang; Martha Sibrian-Vazquez; Jorge O Escobedo; Jialu Wang; Richard G Moore; Robert M Strongin
Journal:  Chem Commun (Camb)       Date:  2015-01-31       Impact factor: 6.222

3.  An extremely simple method for extraction of lysophospholipids and phospholipids from blood samples.

Authors:  Zhenwen Zhao; Yan Xu
Journal:  J Lipid Res       Date:  2009-09-25       Impact factor: 5.922

4.  Measurement of endogenous lysophosphatidic acid by ESI-MS/MS in plasma samples requires pre-separation of lysophosphatidylcholine.

Authors:  Zhenwen Zhao; Yan Xu
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-08-27       Impact factor: 3.205

5.  Simple enrichment and analysis of plasma lysophosphatidic acids.

Authors:  Jialu Wang; Martha Sibrian-Vazquez; Jorge O Escobedo; Mark Lowry; Lei Wang; Yu-Hsuan Chu; Richard G Moore; Robert M Strongin
Journal:  Analyst       Date:  2013-11-21       Impact factor: 4.616

6.  Lysophosphatidic acid activates the RhoA and NF-κB through Akt/IκBα signaling and promotes prostate cancer invasion and progression by enhancing functional invadopodia formation.

Authors:  Young Sun Hwang; Jongsung Lee; Xianglan Zhang; Paul F Lindholm
Journal:  Tumour Biol       Date:  2015-12-10

Review 7.  Lysophospholipid Signaling in the Epithelial Ovarian Cancer Tumor Microenvironment.

Authors:  Yan Xu
Journal:  Cancers (Basel)       Date:  2018-07-09       Impact factor: 6.639

8.  Measurement of phospholipids may improve diagnostic accuracy in ovarian cancer.

Authors:  Lian Shan; Y Ann Chen; Lorelei Davis; Gang Han; Weiwei Zhu; Ashley D Molina; Hector Arango; James P LaPolla; Mitchell S Hoffman; Thomas Sellers; Tyler Kirby; Santo V Nicosia; Rebecca Sutphen
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

Review 9.  Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside.

Authors:  Yan Xu
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.